We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Ciphergen Discovers Protein Biomarkers for Diagnosis of Early-Stage Ovarian Cancer

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Ciphergen Discovers Protein Biomarkers for Diagnosis of Early-Stage Ovarian Cancer"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Ciphergen Biosystems, Inc. presented data on the discovery of several protein biomarkers that may be potential diagnostic markers in detection of early- stage ovarian cancer.

These findings support one of three diagnostic programs that Ciphergen currently has under development for ovarian cancer. These findings were presented at the American Association for Cancer Research Annual Meeting in Los Angeles, Calif.

"Development of a reliable test for the diagnosis of early-stage ovarian cancer should contribute to improving overall survival in patients," said Robert C. Bast, Jr., M.D., Vice President of Translational Medicine, and Professor of Experimental Therapeutics at, M.D. Anderson Cancer Center, University of Texas, co-author of the presentation and member of the Ciphergen Scientific Advisory Board.

Ciphergen and its collaborators discovered four proteins in urine that separate women with early cancer from healthy individuals with a sensitivity of 56% and a specificity of 95%. These results suggest the possibility that these proteins in combination with other biomarkers, could aid in the diagnosis of early-stage ovarian cancer.

To elucidate these findings Ciphergen employed protein expression profiling methods to analyze urine samples from 400 women, including 288 women with epithelial ovarian cancer, 52 with early stage disease and 176 with late stage disease, 74 women with benign ovarian disease and 98 normal, healthy controls.

"These promising results provide the foundation for additional studies across a larger population of women," said Eric T. Fung, M.D., Ph.D., Chief Scientific Officer for Ciphergen Biosystems. "By demonstrating that these findings are reproducible, Ciphergen hopes to advance these markers beyond the clinical validation process and into clinical trials."